3billion쓰리빌리언
394800 · KOSDAQ · ₩394800 · 쓰리빌리언
- Market cap
- ₩178B
- Enterprise value
- ₩174B
- P/E
- 56.0×
- P/B
- 6.0×
- Dividend yield
- 0.0%
- ROE
- 10.7%
- Net margin
- 22.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.2% from the high
₩4,020Today: ₩5,280 – ₩5,690₩20,100
Returns
- 1W+5.7%
- 1M−3.8%
- 3M+7.9%
- 6M−56.4%
- YTD−69.4%
- 1Y−36.7%
- Volume today
- 799,118
- 0.7× the 20-day average
- Traded today
- ₩4.4B
- Listed shares
- 31,822,553
- EPS (12 months)
- ₩100
- Earnings yield 1.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumFlat18.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
3billion stock overview
3billion (쓰리빌리언, KRX: 394800) is listed on KOSDAQ, in the Biotech & Pharma sector. The company applies artificial intelligence to genomic analysis to diagnose rare diseases, offering whole genome and whole exome sequencing-based genetic tests in full-service, data-based, and disease-specific formats. Its shares closed at ₩5,580 on Oct 27, 2026, down 1.24% on the day, giving it a market value of ₩178B.
Key facts
- Market cap
- ₩178B
- Sector
- Biotech & Pharma
- Latest price change
- −1.24%
- As of
- Oct 27, 2026
- Main business
- The company applies artificial intelligence to genomic analysis to diagnose rare diseases, offering whole genome and whole exome sequencing-based genetic tests in full-service, data-based, and disease-specific formats.
Quick answers about 3billion
- What does 3billion do?
- The company applies artificial intelligence to genomic analysis to diagnose rare diseases, offering whole genome and whole exome sequencing-based genetic tests in full-service, data-based, and disease-specific formats. It also sells GEBRA, a variant interpretation software offered as a subscription, and is developing an AI drug discovery platform for early-stage drug candidates. Its customers are mainly physicians and patients, served directly or through distribution partners in 75 countries, with most revenue from outside Korea.
- What is the market cap of 3billion?
- The market capitalisation of 3billion was ₩178B at the close on Oct 27, 2026.
- Who are the largest shareholders of 3billion?
- According to the latest official filings, the largest reported holders are Keum Chang-won (23.98%, as of May 26, 2026); Kim Se-hwan (5.72%, as of Nov 20, 2024); MORGANSTANLEY&COINTLPLC (4.75%, as of Jan 9, 2026).
- When is the next earnings report from 3billion?
- Korean companies rarely announce results dates in advance. Based on when 3billion filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own 3billion?
- Yes. The National Pension Service held 4.02% of 3billion shares as of Oct 2, 2026.
Company profile
The company applies artificial intelligence to genomic analysis to diagnose rare diseases, offering whole genome and whole exome sequencing-based genetic tests in full-service, data-based, and disease-specific formats. It also sells GEBRA, a variant interpretation software offered as a subscription, and is developing an AI drug discovery platform for early-stage drug candidates. Its customers are mainly physicians and patients, served directly or through distribution partners in 75 countries, with most revenue from outside Korea.
Written by AI from the company's latest annual report.
- Korean name
- 쓰리빌리언
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 금창원
- Founded
- Oct 2016
- Listed
- Nov 2024
- Listed shares
- 31,822,553
- Fiscal year ends
- Month 12
- Website
- 3billion.io
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventOct 13, 2026
- 5%+ holding reportOct 2, 2026
- Investor relations (IR) eventOct 1, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- Major sales or supply contractJun 15, 2026
Titles in Korean until English translations are added.
Also known as: 3billion / 쓰리빌리언 / 394800 / KRX:394800
Source: KRX statistical information